# Cerebral Organoids Containing an AUTS2 Missense Variant Model Microcephaly

3

Summer R. Fair<sup>1</sup>, Wesley Schwind<sup>1</sup>, Dominic Julian<sup>1</sup>, Alecia Biel<sup>1</sup>, Swetha
Ramadesikan<sup>1</sup>, Jesse Westfall<sup>1</sup>, Katherine E. Miller<sup>1</sup>, Meisam Naeimi Kararoudi<sup>2,5</sup>, Scott
E. Hickey<sup>4,5</sup>, Theresa Mihalic Mosher<sup>1</sup>, Kim L. McBride<sup>1,3,4,5</sup>, Reid Neinast<sup>3</sup>, James
Fitch<sup>1</sup>, Dean Lee<sup>2,5</sup>, Peter White<sup>1,5</sup>, Richard K. Wilson<sup>1,5</sup>, Tracy A. Bedrosian<sup>1,5</sup>, Daniel
C. Koboldt<sup>1,5</sup>, Mark E. Hester<sup>1,5,6</sup>

9

# 10 Affiliations:

<sup>11</sup> <sup>1</sup>The Steve and Cindy Rasmussen Institute for Genomic Medicine, <sup>2</sup>Center for Childhood Cancer and Blood Diseases, <sup>3</sup>Center for Cardiovascular Research, <sup>4</sup>Division of Genetic and Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA; <sup>5</sup>Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA; <sup>6</sup>Department of Neuroscience,

- 16 The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
- 17

### 18 Corresponding Author:

- 19 Mark E. Hester, Ph.D.
- 20 575 Children's Crossroad
- 21 Columbus, Ohio 43205-2716
- 22 Phone: 614-355-6805
- 23 Fax: 614-355-6675
- 24 Email: Mark.Hester@NationwideChildrens.org
- 25

### 26 **Co-Corresponding Author:**

- 27 Daniel C. Koboldt, MS
- 28 575 Children's Crossroad
- 29 Columbus, Ohio 43205-2716
- 30 Phone: 614-722-0520
- 31 Email: <u>Daniel.Koboldt@NationwideChildrens.org</u>
- 32
- 33 **Figures: 6**
- 34 Supplemental Figures: 6
- 35 Supplemental Tables: 4

#### 36 ABSTRACT

37 Variants in the AUTS2 gene are associated with a broad spectrum of neurological 38 conditions characterized by intellectual disability, microcephaly, and congenital brain 39 malformations. Here, we use a human cerebral organoid (CO) model to investigate the 40 pathophysiology of a heterozygous de novo missense AUTS2 variant identified in a 41 patient with multiple neurological impairments including primary microcephaly and 42 profound intellectual disability. Proband COs exhibit reduced growth, deficits in neural progenitor cell (NPC) proliferation and disrupted NPC polarity within ventricular zone-43 44 like regions compared to control COs. We used CRISPR-Cas9-mediated gene editing to 45 correct this variant and demonstrate rescue of impaired organoid growth and NPC 46 proliferative deficits. Single-cell RNA sequencing revealed a marked reduction of G1/S 47 transition gene expression and alterations in WNT-β-Catenin signaling within proband 48 NPCs, uncovering a novel role for AUTS2 in NPCs during human cortical development. Collectively, these results underscore the value of COs to uncover molecular 49 50 mechanisms underlying AUTS2 syndrome.

51

52 **KEYWORDS:** AUTS2 syndrome, cerebral organoids, CRISPR Cas9, microcephaly,

53 neurodevelopmental disorder, neural progenitor cell

54

#### 55 **INTRODUCTION**

The autism susceptibility candidate 2 (AUTS2) gene was first identified and found 56 disrupted as a result of a balanced translocation event (t7;20)<sup>1</sup> in a pair of monozygotic 57 58 twins with autism spectrum disorder (ASD). Subsequent clinical reports suggest 59 pathological AUTS2 variants are more closely associated with intellectual disability (ID) 60 rather than directly contributing to classical features associated with ASD. AUTS2 is a 61 highly conserved gene that spans 1.2Mb on chromosome 7g11.22 and is comprised of 19 coding exons with a predicted full-length protein of 1,259 amino acids (Fig. 1e). 62 63 Biochemical studies have shown that AUTS2, in association with Casein Kinase 2 64 (CK2), form a polycomb repressive complex 1 (PRC1-AUTS2) which activates rather than represses transcription through recruitment of p300<sup>2</sup>. There are several reported 65 isoforms of AUTS2, including full-length and various C-terminal isoforms, that are 66 expressed throughout brain development<sup>3,4</sup>. Previous studies have shown deletions 67 within the C-terminus isoform spanning exons 9-19 are associated with a severe 68 69 neurocognitive phenotype<sup>3,5</sup>. Other studies have demonstrated several C-terminal 70 isoforms, which are expressed at internal transcriptional start sites in exons 6 and 9, have critical roles during neuronal differentiation<sup>3,4,6</sup>. 71

72 AUTS2 variants are associated with a broad spectrum of clinical features, including low birth weight, feeding difficulties, intellectual disability, microcephaly, 73 74 seizures, brain malformations and mild dysmorphic craniofacial features that are collectively known as AUTS2 syndrome<sup>5</sup>. AUTS2 variants are additionally associated 75 with a host of other neurological conditions such as addiction disorders<sup>7,8</sup>, epilepsy<sup>9</sup>, 76 schizophrenia<sup>10,11</sup>, attention deficit hyperactivity disorder<sup>12</sup> and dyslexia<sup>13</sup>. The diverse 77 78 disease manifestations of AUTS2 variants within the brain underscore the importance of 79 elucidating its role in neurodevelopment.

Animal studies have demonstrated a putative role for AUTS2 in transcriptional activation, RNA metabolism<sup>14</sup>, and cytoskeletal regulation within the central nervous system (CNS) <sup>2,6</sup>. *Auts2* knockdown zebrafish models exhibit overall stunted growth compared to controls, with notable reductions in the forebrain, midbrain and cerebellum<sup>3,15</sup>. Various rodent models of AUTS2 disruption show reductions in the cerebellum<sup>4,6,16</sup> and dentate gyrus<sup>14</sup>. However, these rodent models do not display a

86 microcephalic phenotype, which has hampered our understanding of molecular 87 mechanisms that cause human microcephaly in AUTS2 syndrome. The emergence of 88 human-based model systems of the developing brain such as cerebral organoids (COs) 89 has refined our understanding of the mechanisms controlling human cortical 90 development. In particular, these model systems have revealed human-specific diversity 91 in progenitor quiescence, architecture, and subtypes that recapitulate morphological features of the developing human fetal cortex<sup>17-20</sup>. Several studies modeling primary 92 microcephaly using COs arising from variants in CDK5RAP2<sup>21</sup>, WDR62<sup>22</sup>, and NARS1<sup>23</sup> 93 have uncovered important insights into disease mechanisms<sup>24</sup>. Cumulatively, these 94 reports show cellular deficits in cell cycle progression and cilia formation in apical neural 95 progenitor cells (NPCs) concomitant with reduced cortical expansion in COs<sup>21-23,25,26</sup>. 96

97 Here we describe a human CO model to investigate the pathophysiology of a heterozygous *de novo* missense *AUTS2<sup>T534P</sup>* variant identified in a patient with several 98 99 neurological impairments, including primary microcephaly and profound intellectual 100 disability. Since the majority of all reported pathogenic/likely-pathogenic missense variants cluster near our patient's variant, we envisioned a CO model of the AUTS2<sup>T534P</sup> 101 102 variant would allow us to explore disease mechanisms underlying AUTS2 syndrome. Our results demonstrate AUTS2<sup>7534P</sup> COs show an impaired growth trajectory compared 103 104 to controls, which recapitulates the patient's microcephaly and thus provides a novel 105 model to investigate causal disease mechanisms. Further investigation of proband COs 106 using immunohistochemical techniques revealed reduced NPC proliferation and 107 irregular apical NPC polarity in neural rosettes. To validate whether the proband's CO phenotypes are causal to the AUTS2<sup>T534P</sup> variant, we used CRISPR-Cas9 homology 108 109 directed repair to restore the wild-type sequence (c.1600C>A) and demonstrate 110 phenotypic rescue of impaired organoid growth and proliferative deficits in NPCs compared to proband COs. Single-cell RNA sequencing (scRNA-seq) of proband COs 111 112 showed an underrepresentation of progenitors enriched in expression of G1/S transition 113 genes as well as dysregulated gene expression signatures associated with WNT-β-114 Catenin signaling, which were rescued in gene corrected (GC) control COs. Collectively, 115 these results demonstrate a novel role for AUTS2 during early human cortical

development within NPCs and emphasize the value of COs to uncover pathogenicmechanisms underlying AUTS2 syndrome.

118

#### 119 **RESULTS**

#### 120 Identification of a de novo missense variant in the AUTS2 gene.

121 We report a preschool female who presented with profound intellectual disability. 122 cerebellar hypoplasia, epilepsy, and dysmorphic features (Fig.1a). An MRI of the 123 patient's brain showed enlarged ventricles consistent with cerebral volume loss as well 124 as small cerebellar hemispheres and vermis (Fig.1b-c). Extensive clinical genetic testing 125 was performed on the patient that included karyotype and SNP microarray analysis, 126 biochemical testing for congenital disorders of glycosylation and Smith-Lemli-Opitz 127 syndrome, and DNA methylation testing for Prader-Willi/Angelman syndrome. All of 128 these tests were interpreted by the clinical care team as non-diagnostic. The patient and 129 her parents were then enrolled in an IRB-approved research study for further genomic 130 analysis.

131 To investigate whether the patient's symptoms resulted from underlying genetic 132 causes, whole-genome sequencing (WGS) was performed on the patient and healthy 133 parents (Supplementary Table 1). Our analysis uncovered two candidate-coding 134 variants in the patient without corresponding genetic alterations in the parents, 135 suggesting these variants arose *de novo*. The first candidate was a mosaic splice site 136 variant TULP3 (NM\_003324.4:c.253+1G>T) present at ~23% variant allele frequency. 137 TULP3 variants have not been associated with human disease according to OMIM, and 138 the c.253+1G>T variant does not show constraint for loss-of-function (LoF) variation 139 according to gnomAD (pLI=0), suggesting the splice site variant is not pathogenic. The 140 second identified variant was а de novo missense change in AUTS2 p.(Thr534Pro)). This AUTS2 variant is predicted to be 141 (NM 015570.3:c.1600A>C, damaging by 16/25 in silico tools according to VarSome<sup>27</sup>. Sanger sequencing of the 142 143 family trio confirmed its de novo status (Fig.1d). Although the vast majority of AUTS2 144 variants reported as pathogenic or likely pathogenic to the ClinVar database are 145 predicted to cause loss-of-function changes, five distinct missense variants (including 146 c.1600A>C identified in our patient) have been reported within amino acid residues 529-

147 535 (Fig.1e). Sequence alignment of vertebrate amino acid sequences within the H1 148 region show that this portion of AUTS2 is significantly conserved, suggesting functional 149 importance (Fig.1f). Since few missense variants in *AUTS2* have been reported to 150 cause disease and given its expanding role in a range of neurological disorders, we 151 sought to investigate the underlying pathogenic mechanism of this p.Thr534Pro variant. 152

152

# 153 Expression of AUTS2 in excitatory neurons and progenitor cell types.

To investigate which cell types may be affected by the AUTS2<sup>7534P</sup> variant during 154 155 corticogenesis, we analyzed a published scRNA-seq CO and fetal brain dataset to evaluate AUTS2 expression at cell-type specific resolution<sup>19</sup>. These data indicate 156 157 AUTS2 is expressed in a diversity of cell populations within the developing fetal brain and COs with notable expression in excitatory neurons, radial glia, and intermediate 158 159 progenitors (Supplementary Fig. 1). Given the expression of AUTS2 in these progenitor 160 cell types and the highly dynamic developmental program of NPC proliferation and 161 differentiation during corticogenesis, we sought to investigate its pathophysiology in 162 COs, which are an emerging model system that recapitulate morphological and early 163 neurodevelopmental features of the human brain.

164

# AUTS2 patient COs exhibit patient-specific microcephaly and show proliferative deficits in NPCs.

To investigate the functional role of the AUTS2<sup>7534P</sup> variant during human cortical 167 development, we reprogrammed peripheral blood monocytes from the AUTS2<sup>7534P</sup> 168 169 patient and her parent as a control into human induced pluripotent stem cells (hiPSCs) 170 using Sendai virus-based delivery of Yamanaka transcription factors (Supplementary 171 Fig. 2). hiPSC colonies emerged within seven days post-infection showing tight cell 172 junctions, distinct cell borders, and alkaline phosphatase activity, which are 173 characteristic features of human pluripotent stem cells (Supplementary Fig. 2a,b). We 174 then evaluated the chromosomal integrity and pluripotency of the hiPSCs by 175 karyotyping (Supplementary Fig. 2c) and immunohistochemical analysis of key 176 pluripotency markers, including OCT3/4, SSEA4, NANOG and LIN28 (Supplementary Fig. 2d). Additionally, we confirmed the heterozygous AUTS2<sup>7534P</sup> variant was present in 177

the *AUTS2<sup>T534P</sup>* patient line as demonstrated by Sanger sequencing (Fig. 1d). We then
used these hiPSC lines to generate three-dimensional COs with our undirected
differentiation protocol<sup>28</sup>. Our overall approach for modeling the *AUTS2<sup>T534P</sup>* variant in
COs is summarized in Figure 2a.

182 To investigate whether proband COs modeled the patient's microcephaly, we 183 differentiated proband and parental control hiPSCs into COs and performed a rigorous 184 growth trajectory analysis of COs within a dynamic neurodevelopmental time window of 185 NPC proliferation and differentiation (Fig.1b-d). Proband and parental control COs were 186 indistinguishable by size or gross morphology until day 20 of culture, when proband 187 COs showed a statistically significant reduction in overall growth compared to the 188 parental control from day 20 (Fig.1d). This trend persisted over time (day 20 median cross-sectional area of proband COs was 0.71mm<sup>2</sup> compared to 1.41mm<sup>2</sup> in parental 189 190 control COs) (Fig. 2b-d). By day 28, the median cross-sectional area of proband COs was 1.52mm<sup>2</sup> in proband COs compared to 2.56mm<sup>2</sup> in parental control COs 191 192 (coefficient of variation (CV)=49.01% in proband COs and 44.2% in parental control 193 COs). This trend was also observed across multiple cohorts (n=4), suggesting that the 194 proband COs recapitulate morphological features of the patient's microcephaly.

195 We then tested whether proliferative deficits in NPCs within ventricular-like 196 zones (e.g. neural rosettes) underly the growth deficits observed in proband COs. To 197 perform this analysis, we pulse-labeled proliferating cells in proband and control COs 198 with EdU<sup>29</sup>, and performed a quantitative imaging analysis for the M-phase specific 199 marker, phospho-histone H3+ (pHH3) (see Supplementary Table 2 for all antibodies 200 utilized in this study), and EdU+ cells within neural rosettes. Our analysis revealed a 201 statistically significant reduction in the number of EdU+ and pHH3+ NPCs in proband 202 COs compared to the parental control (Fig. 2e-h). These data suggest proband NPCs 203 have deficits in cell cycle control, which may underlie the reduced growth properties of 204 proband COs.

205

206 **Proband COs exhibit increased asymmetric cellular divisions and ciliary defects** 

207 Since cell cycle control and cellular division is tightly coupled within the VZ during 208 human corticogenesis, we investigated the dividing properties of apical progenitors

along VZ-like zones in proband COs. During early human brain development, NPCs 209 210 self-renew through symmetrical divisions along the ventricular surface to sufficiently expand the pool of NPCs allowing for subsequent neurogenesis<sup>30-32</sup>. After this rapid 211 212 symmetrical expansion of NPCs, they undergo a gradual shift towards dividing 213 asymmetrically to form a daughter NPC and either an intermediate progenitor cell (IPC) 214 or a neuron. Compared to rodent brain development, human brains undergo more 215 extensive symmetrical divisions of apical progenitors and increased basal progenitor proliferation within the oSVZ resulting in a larger frontal cortex<sup>30-32</sup>, a key difference 216 217 which may explain why mutations causing microcephaly in humans are not adequately 218 modeled in the mouse. Several studies have suggested primary microcephaly results in 219 the loss of cortical expansion caused by premature neuronal differentiation due to the progenitors<sup>21,22,33</sup>. This process occurs when progenitors 220 depletion of dividing 221 prematurely undergo asymmetric divisions to generate neurons instead of additional 222 progenitors at an early stage of neurodevelopment. (Fig. 3a).

223 To test whether a similar mechanism of premature asymmetric divisions occurred 224 in proband NPCs, we measured the division angles of SOX2+ apical progenitors at the 225 VZ within our COs using the mitotic spindle marker TPX2 and apical zone marker ZO1 226 (Fig. 3b-c). Approximately one third of divisions within parental control COs were 227 asymmetric (vertical: 18%, oblique: 18%, horizontal: 64%; n=95 cells) whereas nearly two-thirds of divisions in the proband  $AUTS2^{T534P}$  COs were asymmetric (vertical: 31%, 228 229 oblique: 34%, horizontal: 35%; n=126 cells). This approximate two-fold increase in 230 asymmetric divisions within proband COs indicates progenitors may be undergoing 231 premature neuronal differentiation. Taken together, the overall decrease in proliferation 232 and increase in neurogenic, asymmetrical divisions within proband COs suggests that the AUTS2<sup>T534P</sup> variant adversely affects NPC cell cycle dynamics and/or cell fate 233 234 determination.

We next analyzed the primary cilium within neural rosettes as this structure is critical in establishing NPC columnar organization within the VZ and is directly involved in cell cycle kinetics of various cell types, including NPCs. Several microcephalic phenotypes have been linked to disruptions in primary cilium dynamics<sup>22,34-36</sup>. We found VZ-like structures within proband COs that lacked NPC columnar organization and

240 uniform polarity. Specifically, they exhibited disrupted microtubule networks within 241 rosettes, as shown by their irregular acetylated tubulin immunoreactivity (Fig. 3g,h,j) 242 compared to controls (Fig. 3e-f, i). Additionally, we observed a statistically significant 243 reduction in the length of proband ARLB13B+ cilia compared to controls (Fig. 3k). 244 Collectively, these results suggest the proband COs exhibit deficits in ciliary properties and organization with a concomitant loss of NPC polarity within CO rosettes. Since 245 246 primary cilium formation and resorption is imperative to the progression of the cell cycle, the loss of NPC polarity in proband COs provides further evidence that the AUTS2<sup>T534P</sup> 247 248 variant impairs their proliferative capacity.

Given the established role of AUTS2 in neuronal migration<sup>6</sup>, we then evaluated 249 250 whether there were any overt abnormalities in progenitor cell migration by analyzing the 251 distribution of TBR2+ intermediate progenitor cells (IPCs) surrounding neural rosettes in 252 proband COs. We did not observe any marked differences in the distribution of TBR2+ 253 IPCs demarcating neural rosettes within both proband and control COs (Supplementary 254 Fig. 3a). Further, no IPCs were detected within proband or control rosettes as expected, suggesting the AUTS2<sup>T534P</sup> variant may not substantially affect progenitor migration. To 255 256 investigate AUTS2 expression in proband COs, we observed both cytoplasmic and 257 nuclear expression of AUTS2 in NPCs, similar to the parental control, and verified 258 AUTS2 staining specificity using a blocking peptide directed against the AUTS2 antibody utilized. These data suggest the AUTS2<sup>7534P</sup> variant does not alter normal 259 260 AUTS2 expression patterns (Supplementary Fig. 3b). We also observed that a subset of 261 IPCs were both AUTS2+ and TBR2+ in both proband and control COs, which is 262 consistent with our synthetic scRNA-seq analysis (Supplementary Fig. 1).

263

264 Growth area and NPC proliferative deficits in proband COs are rescued by gene 265 correction.

To investigate whether the phenotypes we observed in proband COs were caused by the  $AUTS2^{T534P}$  variant, we gene corrected this alteration to the wild-type sequence using CRISPR-Cas9 homology directed repair (Fig. 4a). A small guide (sg) RNA (20 base pairs) targeting the AUTS2 variant region was designed that contained <2 base pair matches to other sequences in the genome to ensure precise gene targeting. Additionally, a silent edit was

271 inserted in the single-stranded oligo donor (ssODN) sequence to disrupt repeated sgRNA 272 binding and subsequent re-cutting by Cas9 after successful editing (Fig. 4b). sgRNA and 273 ssODN sequences are provided in Supplementary Table 3. Synthego's Inference of CRISPR 274 Edits (ICE) software tool was then used to measure the frequency of successful gene editing. 275 We then generated single iPSC clones, screened ~100 of them using Sanger sequencing, and 276 confirmed three clones showed both successful gene correction (c.1600C>A) and introduction 277 of the silent gene edit (c.1608G>A). Next, we verified pluripotency markers using 278 immunofluorescence analysis and chromosomal stability using karyotype analysis in the GC 279 hiPSC line prior to generating COs (Supplementary Fig. 2b-d).

280 We then generated COs using an optimized protocol to enhance organoid reproducibility in our cultures<sup>37,38</sup> and to test whether GC of the AUTS2 variant rescued the 281 282 microcephalic phenotype we observed in proband COs (Fig. 4c-g). This protocol obviates the 283 requirement to encapsulate neuroepithelial bodies and generates morphologically reproducible and robust COs compared to prior protocols<sup>37,38</sup>. Consistent with our previous studies, proband 284 285 COs generated by this method showed a reduction in growth compared to parental control COs (day 30 median cross-sectional area of proband COs was 1.44 mm<sup>2</sup> compared to 2.43 286 287 mm<sup>2</sup> in parental control COs) (Fig. 4h,i,g). In contrast, our GC COs showed a statistically 288 significant increase in cross sectional area compared to proband COs, suggesting phenotypic rescue and that the AUTS2<sup>7534P</sup> variant contributes to organoid growth deficits (day 30 median 289 cross-sectional area of GC control COs was 1.68 mm<sup>2</sup>,75<sup>th</sup> percentile cross-sectional areas 290 were 1.55 mm<sup>2</sup> in proband COs compared to 2.11 mm<sup>2</sup> in GC control COs and 2.81 mm<sup>2</sup> in 291 292 parental control COs (Fig. 4i,j,g). However, no statistically significant difference in cross-293 sectional area was observed between the parental control and GC control COs. This finding 294 may suggest the gene correction results in a partial rescue and/or highlights the variability in 295 growth properties of COs arising from intrinsic differences between hiPSC lines (Fig. 4r). The 296 latter scenario underscores the value of performing these types of analyses with a GC hiPSC 297 line. Our optimized CO generation protocol resulted in a significant reduction of the CV in CO 298 area measurements across groups compared to our earlier CO area growth analysis 299 (CV=12.78% in proband COs, 26.86% in parental control COs, and 29.77% in GC control 300 COs), which suggests this improved CO generation protocol lowers organoid-to-organoid 301 variability.

302 Next, we tested whether NPC proliferative deficits in proband COs were rescued by the 303 AUTS2 variant gene correction. Similar to our prior experiment, we pulse-labeled proliferating 304 cells in COs with EdU and then performed a quantitative imaging analysis for pHH3+ and 305 EdU+ cells within neural rosettes across all organoid groups (Fig. 4k-p). Although an increased 306 trend in the number of EdU+ was observed in the GC control compared to proband COs, this 307 increase did not reach statistical significance (Fig. 4r). However, a statistically significant 308 increase in the number of pHH3+ NPCs was observed in the GC control compared to proband 309 NPCs (Fig. 4s). In addition, no significant difference was observed between the parental 310 control and the GC control, suggesting phenotypic rescue, and thus providing further evidence that the AUTS2<sup>7534P</sup> variant contributes to deficits in NPC proliferation (Fig. 4s). 311

312

# 313 Single-cell RNA sequencing reveals a susceptible population of NPCs in proband COs 314 that is rescued by gene correction.

315 To determine cell-type specific transcriptomic signatures underlying the proband COs 316 microcephalic phenotype, we performed scRNA-seq analysis in day 30 proband COs (n=8 317 organoids pooled per group; Fig. 5). We performed unsupervised clustering on gene 318 expression profiles from an integrated dataset of 35,633 cells and identified ten composite 319 clusters using canonical marker genes (Supplementary Fig. 4). Since the scope of our study 320 primarily concerned NPCs and differentiated immature neurons, we subclustered them for 321 further analysis. This sub-clustering resulted in five cell types from an integrated dataset of 322 17,752 cells, which were comprised of EOMES+ intermediate progenitor cells (IPCs), 323 STMN2+/GAP43+/TBR1+ immature neurons, and three classes of SOX2+ neural progenitor 324 cells (NPCs) (Fig. 5a,b). Upon initial analysis, we observed a drastic reduction in the relative 325 proportion of Type 2 NPCs in proband COs compared to both controls (Fig. 5c-h). Strikingly, 326 Type 2 NPCs constituted approximately 22% of cells within parental control COs, but only 327 0.25% in proband COs. This underrepresented NPC population was significantly rescued in 328 GC control COs showing a 22-fold increase of Type 2 NPCs (5.5% of total) compared to proband COs, suggesting the reduction of this cell type is related to the AUTS2<sup>T534P</sup> variant. 329 330 We also observed a two-fold increase in the percentage of immature neurons in proband COs 331 (29%) compared to parental control COs (14%), which supports our earlier results showing 332 increased asymmetrical divisions and subsequent premature neuronal differentiation in

proband COs. The GC control also showed a decrease in the percentage of immature neurons 333 334 compared to proband COs (from 29% in proband COs to 23% in GC control COs), suggesting 335 that gene correction of the AUTS2 variant partially restores the proper timing of neurogenesis 336 in COs. We also noted a nearly two-fold increase in the percentage of IPCs in proband COs, 337 which constitute 7% of all subclustered cells but only 3-4% in control COs. Analysis of AUTS2 338 expression in our sc-RNA seg data showed similar levels across both proband and control groups in NPCs and in immature neurons, suggesting the AUTS2<sup>T534P</sup> variant does not affect 339 340 mRNA stability (Supplementary Fig. 5).

341 Next, we investigated gene expression signatures enriched in Type 1 and Type 3 NPCs. 342 Type 1 NPCs were enriched for G2/M phase gene expression signatures such as MKI67 and 343 TOP2A and Type 3 NPCs were enriched for FABP7 and SOX9, transcription factors which are critical for NPC proliferation and promote neuronal and glial fate specification<sup>39-42</sup> (Fig. 5b, 344 345 Supplementary Fig. 4). Type 1 NPCs were comprised of similar percentages within proband 346 (24.8%) and parental control COs (26.7%) and were elevated approximately by 10% in GC 347 control COs. Type 3 NPCs showed an approximate 5% increase in proband COs compared to 348 both control COs. The significance of these differences is unknown and warrants future 349 investigation.

350 To determine specific biological processes and molecular functions that characterize 351 Type 2 NPCs, we performed a gene ontology analysis from the top enriched gene expression signatures identified in Type 2 NPCs (Fig. 5i). Type 2 NPCs were enriched for the GO terms: 352 353 anterior/posterior pattern specification (GO:0009952), ribosome assembly (GO:0042255), 354 G1/S transition of mitotic cell cycle (GO:0000082), protein-DNA complex assembly 355 (GO:0071824), and others (Fig. 5i). Further analysis of gene signatures identified within the 356 anterior/posterior pattern specification gene ontology revealed genes associated with midbrain 357 and hindbrain specification (e.g. OLIG3, HOXA2) (Supplementary Fig. 6). Thus, AUTS2 may 358 play a critical role in specifying these cells fates and may explain why AUTS2 syndrome 359 patients display cerebellar hypoplasia. Additionally, the Type 2 NPCs were enriched for 360 CCND1, EIF4EBP1, CDK6, CCND2, and other gene expression signatures, all of which 361 contribute to the G1-S transition phase of the cell cycle (Fig. 5). Expression analysis of these 362 cell cycle genes showed significant reductions in proband COs, which were restored in GC COs (Fig. 5k). Collectively, these findings suggest that the AUTS2<sup>T524P</sup> variant in proband COs 363

364 leads to a selective loss of proliferating progenitors, which is consistent with a reduced 365 percentage of EdU+ and pHH3+ progenitors and consequential microcephalic phenotype in 366 proband COs compared to controls (Fig. 2e-h,4h-t). These results suggest AUTS2 plays an 367 important role in the progression of the cell cycle within NPCs, which is critical for proper timing 368 of human corticogenesis.

369 Proband NPCs show dysregulated gene expression associated with WNT-β-catenin
 370 signaling, chromatin modification, and gliogenesis.

371 To further investigate underlying molecular mechanisms affecting NPC proliferative 372 deficits in AUTS2 patient COs, we performed gene ontology analyses from genes identified 373 within the Type 1 and 3 NPC clusters that were differentially expressed in comparison to both 374 parental and GC control COs. In Type 1 NPC, we observed differentially expressed genes 375 (DEGs) that were enriched for the GO terms: brain development (GO:0007420), CNS neuron 376 differentiation (GO:0021953), WNT signaling pathway (GO:0016055), chromatin silencing 377 (GO:0006342), and others (Fig. 6a). Of note, the chromatin modifying gene, HMGA1, showed 378 reduced expression in proband COs (Fig. 6b), which has been shown to play an important role 379 in controlling the neurogenic potential of NPCs and the developmental timing of 380 gliogenesis<sup>43,44</sup>. Other chromatin modifying genes, *HIST1H2AG* and *KCNQ1OT1*, were also 381 dysregulated. Our analysis also identified increased expression levels of MAP2, which is 382 consistent with our earlier finding that proband NPCs are undergoing premature neuronal 383 differentiation. NFIB and FGFR3 expression levels were also induced in proband Type 1 384 NPCs, suggesting these progenitors show a propensity towards glial cell differentiation. 385 Interestingly, we observed increased expression of the homeobox transcription factor, TSHZ2, 386 and the neural cell adhesion gene, CNTNAP2, both of which have been previously identified as AUTS2 target genes in mouse studies<sup>45</sup> (Fig. 6b). We then focused our analysis on those 387 388 DEGs associated with WNT signaling as numerous studies have underscored its critical role in regulating NPC proliferation and differentiation within the ventricular zone<sup>46-48</sup>. *CTNNB1*, which 389 390 is the major signal transducer of WNT signaling, was significantly reduced in proband COs 391 within both Type 1 and 3 NPCs and immature neurons. We also observed alterations in the 392 expression of multiple genes in proband COs compared to control COs, which function in 393 regulating WNT signaling activity such as RSPO3, SFRP2, GPC4, and SULF2 (Fig. 6c,d). 394 Cyclin D1 (encoded by the CCND1 gene) is a well-characterized target for WNT- $\beta$ -catenin signaling, which promotes G1/S phase transition of the cell cycle<sup>49,50</sup>, was reduced in proband NPCs compared to controls (Fig. 5k). Collectively, our data suggests that proband NPCs show deficits in WNT- $\beta$ -catenin signaling, which may underly their proliferative deficits and impairment to transition through the G1/S phase of the cell cycle.

399 We then performed the same type of GO analysis for Type 3 NPCs and observed DEGs 400 that were enriched for the GO terms: brain development (GO:0007420), WNT signaling 401 pathway (GO:0016055), regulation of glial cell differentiation (GO:0045685), cell division 402 (GO:0051301), and others (Fig. 6e). Similar to Type 1 NPCs, Type 3 NPCs showed reduced 403 expression of HMGA1 and dysregulated expression of the WNT signaling regulators, RSPO3. 404 SFRP2, and ZIC1. In addition, we observed dysregulated expression of the centromere 405 binding genes, CENPF and CENPW, which may contribute to the polarity and mitotic deficits in 406 proband NPCs compared to controls. Increased expression of the HES1 and ID3 genes were 407 also observed in proband NPCs. Previous studies have suggested that HES1 and ID3 promote the specification of neural precursors towards an astrocyte fate<sup>51,52</sup>, which suggests proband 408 409 NPCs may have an altered propensity to differentiate into glial identities.

410 Next, we examined the DEGs identified in immature neurons from our sc-RNA seq data. 411 Mouse studies have underscored a critical role for AUTS2 in controlling neuronal gene 412 expression and specifying neuronal cell fates, however few studies have examined the role of 413 AUTS2 in human corticogenesis and its biological link to intellectual disability observed in 414 AUTS2 syndrome patients. Similar as described above, we performed a GO analysis on 415 DEGs from immature neurons and identified the following enriched biological processes: 416 synapse maturation (GO:0060074), cholesterol biosynthesis (R-HSA-191273), glial cell 417 differentiation (GO:0010001), and cytoskeleton organization (GO:0045104), among others 418 (Fig. 6g). We observed dysregulated expression in the synaptic maturation genes, NEFM, 419 *RELN, NRXN1*, and reduced expression of genes controlling cholesterol metabolism such as ACAT2 and HMGCS1 (Fig. 6h). Other altered gene expression levels were observed in genes 420 421 regulating cytoskeletal organization: SMC1A and NEFM; and neurite morphogenesis: DCC 422 and *MDK*. Interestingly, *Nrxn1* and *Reln* were previously identified as AUTS2 target genes in mouse studies using ChIP Seq<sup>45</sup>. In addition, *NRXN1, DCC, RELN*, and *SMC1A* have all been 423 424 implicated in ASD and ID and are designated Simons Foundation Autism Research Initiative (SFARI) genes<sup>53-57</sup>. Further studies are warranted to understand the impact of these altered 425

gene expression patterns on synaptic maturation and activity during neurodevelopment using *in vitro* and *in vivo* models of *AUTS2* deficiency and whether they are linked to cognitive
deficits in ASD/ID patients.

- 429
- 430

#### 431 DISCUSSION

432 This study provides novel molecular insights into AUTS2 function within NPCs, 433 which may underly the neurological manifestations of microcephaly and syndromic 434 intellectual disability observed in AUTS2 syndrome patients. Previous animal studies 435 have identified a role for AUTS2 in transcriptional activation, RNA metabolism, and 436 cytoskeletal regulation in excitatory neurons. However, these animal models of AUTS2 437 deficiency do not develop reductions in cortical volume (i.e. microcephaly) and therefore 438 may not adequately recapitulate disease mechanisms underlying AUTS2 syndrome 439 within the cerebral cortex.

Here we present a patient with a *de novo* pathogenic AUTS2<sup>T534P</sup> missense 440 441 variant who presents with AUTS2 syndrome. We established a CO model of this patient to investigate the human-specific pathogenesis of AUTS2<sup>7543P</sup> in the early developing 442 443 brain. Our results indicate that AUTS2 deficiency leads to a microcephalic phenotype, 444 which dysregulates cell cycle dynamics within NPCs, leading to a subsequent reduction 445 in proliferation, ciliary defects and the selective loss of progenitors enriched for gene 446 expression associated with G1/S cell cycle transition. Further, scRNA-seq analysis 447 revealed deficits in WNT-β Catenin signaling in NPCs, which may underly their 448 proliferative deficits. Multiple studies have underscored the critical role of β-Catenin 449 within NPCs during neurodevelopment. For example, conditional deletion of β-Catenin 450 in mouse cortical NPCs led to reduced cell proliferation and disruptions in the organization of the neuroepithelium<sup>47</sup>. Conversely, overexpression of a stabilized form 451 of  $\beta$ -Catenin in NPCs increased cell proliferation<sup>46</sup>. Additionally, focal depletion of  $\beta$ -452 453 Catenin within NPCs of the mouse ventricular zone caused premature cell cycle exit and neuronal differentiation<sup>48</sup>. However, it is unclear how AUTS2 deficiency is related to 454 455 deficits in WNT- $\beta$  Catenin signaling, although a few studies have suggested WNT- $\beta$ 456 Catenin signaling and AUTS2 share common downstream targets. For example, the

457 WNT target gene, Cachd1, was recently identified as an RNA transcript that can be bound and regulated by AUTS2<sup>14</sup>. Other shared AUTS2 targets identified using ChIP 458 Seq<sup>45</sup> and targets of Wnt signaling using RNAseg<sup>58</sup> include *Fzd1* and *Nfia*. It is also 459 460 plausible that altered expression of chromatin modifying genes observed in proband 461 NPCs may dysregulate downstream WNT target gene expression. Interestingly, 462 CTNNB1 gene mutations have been associated with dysmorphic features, microcephaly, and intellectual disability in patients<sup>59,60</sup>, clinical symptoms all of which 463 464 have been observed in AUTS2 syndrome patients. Further investigation is required to determine whether overexpression of CTNNB1 in AUTS2<sup>T543P</sup> COs can rescue NPC 465 466 proliferative deficits.

467 More recent work by Liu et al demonstrated the HX domains of AUTS2, including 468 the HQ-rich domain within exon 9, are critical for the previously characterized AUTS2-469 P300 complex<sup>61</sup>. Variants that fall within this HQ-rich domain are associated with 470 neurological symptoms such as microcephaly and intellectual disability-a strikingly 471 similar clinical presentation to Rubinstein-Taybi syndrome, which is caused by pathogenic variants in *CREBBP/P300*. In this study, the AUTS2<sup>T534P</sup> variant is deficient 472 473 in recruiting P300 to the PRC1.5-AUTS2 complex, leading to transcriptional 474 dysregulation of downstream target genes. Although this work provides important insight to the mechanism by which the AUTS2<sup>T534P</sup> variant alters PRC1.5-AUTS2 475 476 activity, our study provides novel molecular insights into how this variant leads to 477 pathogenesis in the developing human brain.

478 One of the challenges associated with CO modeling is variability associated with 479 utilizing different hiPSC lines and organoid-to-organoid variability present within a 480 particular experimental batch. We addressed these challenges by 1) adapting a 481 modified CO protocol to enhance organoid reproducibility, and 2) generating an 482 isogenic, gene-corrected hiPSC line. By gene correcting this variant in proband hiPSCs, 483 we determined the proliferative and molecular deficits observed in proband NPCs were 484 directly linked to the AUTS2 variant. In GC COs, we observed a statistically significant 485 rescue of overall growth compared to proband COs, although overall growth of GC COs 486 did not match that of parental control COs. However, at the molecular level, GC COs 487 showed a statistically significant rescue in the percentage of proliferating pHH3+ NPCs

488 compared to proband COs. Additionally, sc-RNAseq analysis of GC COs showed a 489 rescue of molecular alterations underlying proliferative deficits within proband NPCs.

490 Our sc-RNAseg analysis also uncovered an NPC population that was strikingly 491 underrepresented in proband COs. GO analysis revealed these Type 2 NPCs were 492 enriched in gene expression signatures associated with G1/S cell cycle transition in 493 addition to marker genes associated with midbrain and hindbrain specification. The loss 494 of these cell fates in combination with proliferative deficits observed in proband NPCs, 495 most likely contributes to the microcephalic phenotype observed in proband COs. 496 Interestingly, the AUTS2 syndrome patient described here also displays cerebellar 497 hypoplasia (Fig. 1b), which may be the result of deficits in hindbrain fate specification. Investigation of the AUTS2<sup>T534P</sup> variant using cerebellar organoids would provide 498 499 greater mechanistic insight into AUTS2 function during cerebellum development.

500 Future studies are required to expand upon our findings and evaluate the 501 mechanisms by which AUTS2 controls cell cycle progression in early NPCs. 502 Additionally, other disease-causing variants, such as those found within the mutation 503 hotspot within the ninth exon of AUTS2, warrant further investigation. Since AUTS2 is a 504 master neuronal transcriptional activator, microcephaly in AUTS2 syndrome patients 505 may arise from dysregulation of multiple downstream target genes. Thus, future studies 506 are required to elucidate how transcriptional activation of AUTS2 variants is altered in 507 NPCs and differentiated neuronal progeny. Our results show a critical role for AUTS2 in 508 NPC proliferation and neuronal specification during early human cortical development, 509 deficits of which may contribute to the clinical manifestations observed in AUTS2 510 syndrome patients. In sum, this study highlights the value of COs to advance our 511 understanding of mechanisms underlying AUTS2 syndrome with the ultimate goal of 512 developing therapeutic strategies for patients.

513

514

#### 515 MATERIALS & METHODS

516

**Subjects**. The proband and both of her parents were enrolled as part of an Institutional Review Board (IRB) approved study (IRB:11-00215: Rare Diseases/Genome Sequencing) within the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children's Hospital. Informed consent was provided for all study participants to partake in this research and to have this work published. Genomic analysis was performed on DNA isolated from either peripheral blood or saliva samples.

523

524 Whole genome sequencing and analysis. Whole-genome sequencing was performed 525 for all three members using an Illumina HiSeq4000 instrument according to 526 manufacturer protocols. Reads were mapped to the GRCh37 reference sequence, and 527 secondary data analysis was performed using Churchill (Kelly et al., 2015), which 528 implements the GATK "best practices" workflow for alignment, variant discovery and 529 genotyping. Variants were called using GATK 4.0.5.1, and the resulting VCF file was 530 annotated with genes, transcripts, function classes, damaging scores, and population allele frequencies using an in-house pipeline built around the SNPeff annotation tool.<sup>62</sup> 531 532 Our general approach to variant annotation and prioritization has been previously described.<sup>63</sup> After removing common variants (MAF>0.01 in the gnomAD v.2.1.1 533 534 database), we selected for further analysis all splice site, frameshift, and nonsense 535 variants, as well as missense variants predicted to be damaging by SIFT (score<0.05), 536 Polyphen (score>0.453), GERP (score>2.0), or CADD (Phred score>15). Because of 537 the severe presentation and lack of a significant family history, we prioritized candidate 538 de novo mutations consistent with dominant inheritance, but recessive and X-linked 539 models were also considered.

540

541 **CO culture.** *iPSC cell line generation and quality control testing:* Peripheral blood 542 mononuclear cells (PBMCs) were reprogrammed to human induced pluripotent stem 543 cells (hiPSCs) using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher) 544 according to manufacturer's instructions. All hiPSC lines used in this assay were

545 rigorously tested for pluripotency markers, tested negative for mycoplasma, and 546 underwent short tandem repeat (STR) profiling analysis (LabCorp) to authenticate purity 547 of cell lines. In addition, all hiPSC lines were tested for live alkaline phosphatase activity 548 using the Alkaline Phosphatase Live Stain kit (Thermofisher) according to 549 manufacturer's instructions. *iPSC culture maintenance:* All lines were maintained under 550 feeder-free and defined, serum free medium conditions. iPSCs were cultured in either 551 mTeSR (StemCell Technologies) or Essential 8<sup>™</sup> Medium (ThermoFisher) and 552 passaged on vitronectin-coated tissue culture plates using standard methods. CO 553 generation: All media formulations for CO generation are described in Supplementary 554 Table 4. The initial cohorts of whole brain CO used in Figures 2 and 3 were generated according to our previously described protocol<sup>28</sup>. CO culture media were exchanged 555 556 every third day. An adapted whole brain CO generation protocol was used for 557 subsequent analyses in Figures 4 and 5 optimized to increase CO reproducibility. In this 558 CO protocol, iPSC lines were thawed from cryopreservation and passaged a minimum 559 of one time and maintained in culture for at least seven days. iPSCs at 65-85% 560 confluency were pre-treated with 5µM Y-27632 ROCK Inhibitor for 1 hour and then 561 processed into single cells with TrypLE dissociation reagent (ThermoFisher). Cells were 562 then resuspended in iPSC media supplemented with 5µM ROCK inhibitor at a 563 concentration of 40 cells/µl. Then, 100µl of the suspension was transferred into each 564 well (4,000 cells/well) of a non-tissue culture u-bottom 96-well plate. The plates were 565 then balanced and spun down at 400g for 4 minutes. Although the embryoid bodies 566 (EBs) began to noticeably form within a few hours of seeding, plates were left 567 undisturbed for 72 hours for optimal EB formation. After EB formed, media and 568 unincorporated cells were aspirated from each well and replaced with 150µl of fresh 569 Neural Induction Medium (NIM). The NIM was replaced every other day until Day 10. On Day 10, EBs were transferred to a larger plate format (10cm<sup>2</sup> untreated dishes) with 570 571 Cerebral Organoid Expansion Medium (COEM) + 2% Matrigel and placed on an orbital 572 shaker. Then, 72 hours later, the COEM was removed and replaced with Cerebral 573 Organoid Growth & Differentiation Medium (COGDM) + 1% Matrigel. Organoids 574 received fresh COGDM three times per week for the remainder of their time in culture. 575 All media formulations were prepared according to our previous studies<sup>28</sup>.

576 AUTS2 exon 9 PCR amplification and Sanger DNA sequencing. Polymerase chain 577 reaction (PCR) was performed using the JumpStart REDTag ReadyMix Reaction Mix 578 (Sigma) with the following experimental conditions: 200ng of genomic DNA, 25µM of 579 primers (AUTS2 Exon9-Forward primer: 5'-TCTTGCGACAGGAACTGAACA-3', AUTS2 580 Exon9-Reverse primer: 5'-GTGCTCTACTTATCCTCACATTTTGC-3'), and the 581 JumpStart REDTag ReadyMix. PCR cycling parameters were the following: initial 582 denaturation 2 minutes at 94° followed by 35 cycles at 94° for thirty seconds, thirty 583 seconds at 60°, one minute at 72°, and a final extension of five minutes at 72°. Agarose 584 gel electrophoresis was used to visualize PCR products and then were excised and 585 extracted using the QIAquick Gel Extraction Kit (Qiagen). Purified PCR products were 586 then processed for Sanger DNA sequencing (Eurofins) using both AUTS2 Exon9F and 587 AUTS2 Exon9R primers.

588

589 CRISPR/Cas9 AUTS2 variant gene correction and iPSC clone screening. The 590 patient hiPSC line harboring the AUTS2<sup>7534P</sup> variant was gene corrected in collaboration with Synthego with the specific gene correction and silent edit:  $AUTS2^{P534T}$  (c.1600C>A, 591 592 c.1608G>A) (Fig. 4b). A small guide (sg) RNA (TGTGCTGGTGCGTGTGCTGG) was 593 designed that contained <2 base pair matches to other sequences in the genome to 594 ensure precise gene targeting. The sgRNA was then complexed with Cas9 to generate 595 a ribonucleoprotein complex and together with the single-stranded oligo DNA donor (Supplementary Table 3) were nucleofected into AUTS2<sup>T534P</sup> hiPSCs. 596 Synthego's 597 Inference of CRISPR Edits (ICE) software tool was then used to measure the frequency 598 of successful gene editing. iPSCs were then dissociated with TrypLE Express 599 (Thermofisher) and seeded at 0.5 cells/well into a 96 well dish and allowed to expand to 600 confluency. Genomic DNAs from single iPSC clones were then isolated and screened 601 using Sanger sequencing to confirm successful gene correction and introduction of the 602 silent gene edit.

603

604 **Conservation analysis.** The full length AUTS2 isoform sequence (AUTS-isoform 1 on 605 UniProtKB) were selected from UniProtKB database. UniProtKB's in-built ClustalW 606 (Clustal Omega) alignment tool was used to perform sequence alignment. The following

default alignment parameters were used- default transition matrix Gonnet, gap penalty
of 6 bits, gap extension of 1 bit. The default alignment algorithm HHAlign (Soding J,
2005.) was used to perform sequence alignment.

610

611 **Collation of AUTS2 exon 9 variants**. Exon information of *Homo sapiens AUTS2* full 612 length isoform (Ensmbl ID- ENST00000342771.10) was determined based on UCSC 613 Genome browser annotation. Based on this exon 9 mapping, all unique *AUTS2* exon 9 614 variants on ClinVar, LOVD (Leiden Open Variant Database) and HGMD were collected 615 and tabulated.

616

617 Immunohistochemistry. Fixation: Cerebral organoids (COs) were fixed in 4% 618 Paraformaldehyde (PFA, Electron Microscopy Sciences, 15713)/DPBS (Gibco, 14190-619 144) at 4°C overnight. The next day, COs were placed on a shaker in PFA solution at 620 RT for 10-15 minutes to finalize fixation. Once entirely fixed, residual PFA was removed 621 with three DPBS washes. COs then underwent a sucrose gradient: first, COs were 622 equilibrated to 10% Sucrose (Sigma Life Sciences, S7903-250G)/1% Antibiotic-623 Antimycotic (Gibco, 15240-062)/ DPBS solution overnight. Then, COs were transferred 624 to a 30% sucrose/1% Antibiotic-Antimycotic/DPBS solution to equilibrate overnight 625 again. Preparation for Cryosectioning: The COs and the 30% sucrose solution were 626 inverted into a petri dish and transferred to excess optimal cutting temperature (OCT) 627 solution (Sakura Finetek USA Inc, 4583) with a sterile, trimmed transfer pipet. Up to five 628 COs were placed quickly into the mold, minimally rearranged in a grid-like fashion, and 629 immediately frozen in a bath of dry ice pellets and methanol. The COs were stored at -630 80°C until sectioned. Cryosectioning: The embedded tissue was removed from -80°C 631 and mounted on a cryostat chuck with dry ice. The mounted tissue was placed in the 632 cryostat (ThermoFisher, 957020) to equilibrate to -14°C for approximately one hour. 633 Then, the tissue was sectioned at 20µm directly onto positively charged glass slides 634 (Fisherbrand, 1255017) in the cryostat. The slides were stored at -30°C until further 635 processing. Staining: Slides containing sections were then thawed at room temperature 636 (RT) for at least twenty minutes, outlined with a hydrophobic maker (Life Technologies, 637 008899), and re-hydrated in PBS. Slides were then incubated with blocking solution

638 containing 0.1% Triton X-100/10% donkey serum/Tris Buffer Solution (TBS) for one 639 hour at room temperature. Slides were then incubated with primary solution (blocking 640 solution, antibodies per dilutions described in Supplementary Table 2) for 16-24 hours 641 at 4°C. Slides were then rinsed three times with TBS solution. Then, secondary solution 642 (blocking solution, species-appropriate secondary antibodies and DAPI) was added and 643 incubated for 2 hours at RT. Residual secondary antibodies were removed with three 644 TBS washes. Slides were then immediately cover-slipped with Fluoromount-G® 645 (SouthernBiotech, 0100-01). *Imaging:* Images were captured with confocal microscopy 646 on a scanning laser confocal microscope (Zeiss LSM 800).

647

648 CO phenotype characterization. Organoid area quantification: Organoid cross-649 sectional areas were extracted from phase contrast images using FIJI and analyzed for 650 trends in GraphPad Prism X. *Mitotic angle analysis:* Angle calculations were determined 651 using fixed organoid slices stained with TPX2, ZO1, and DAPI to label spindle 652 microtubules during mitosis, the ventricular surface, and cell nuclei, respectively. First, 653 the ventricular surface was outlined using the Adobe Photoshop 2020 Curvature Pen 654 Tool with a solid line one pixel in width. Next, the Add Anchor Point Tool was used to 655 ensure the outline closely adhered to the border of the ventricular surface. ZO1 and 656 DAPI were used to describe the ventricular surface. Second, the line of cleavage was 657 similarly drawn between the TPX2 signals of cells caught in mitosis. Third, the line of 658 cleavage was copied and transposed to intersect the ventricular surface outline at its 659 closest point using the Path Selection Tool. Fourth, the outlined images were quantified 660 on ImageJ (FIJI) using the Angle tool to measure the angle of cleavage as defined by 661 the acute angle formed by the transposed line of cleavage and the intersecting portion 662 of the ventricular surface for each cell. Finally, each cell was given a division 663 classification of vertical, oblique, or horizontal according to its angle of division falling 664 between 0-30°, 30-60°, or 60-90°, respectively. EdU and pHH3 analysis: First, rosette 665 boundaries were drawn on a merged image of Edu, pHH3 and DAPI signal using the 666 Polygon Selection Tool in FIJI. Then, EdU+ and pHH3+ cells were then manually 667 quantified, and trends were analyzed in GraphPad Prism X. Cilia length and count 668 analyses: Tissue sections from the parental control and proband lines were stained with

ARL13B, SOX2 and DAPI according to our IHC protocol. The sections were then surveyed to locate and collect z projection images of rosettes. The upper and lower boundaries of the z projection were defined by ARL13B signal (i.e. appearance of cilia). A maximum projection was then generated and used in subsequent analyses, where cilia length and count as well as rosette area were determined using the ROI and measurement tools in FIJI (ImageJ v.2.0.0-rc-69/1.52p). All statistical analyses were performed using one-way ANOVA with Tukey's multiple comparisons test.

676

677 Single-cell RNA sequencing sample processing. Cerebral organoids were pooled in 678 groups of eight (per line) and prepared for single-cell RNA sequencing as previously 679 described<sup>28</sup>. In brief, organoids were dissociated into a single cell suspension using a gentleMACS Octo Dissociator (Miltenyi) with the manufacturer's "37 °C\_ABDK\_02" 680 681 program. Then, 2 mL solution of Accumax (Sigma, A7089) was transferred into a 682 gentleMACS C-tube (Miltenvi, 130-093-237), organoids were placed in this solution and 683 processed using an Octo-Dissociator instrument (Miltenyi). After the program 684 completed, 10mL of DPBS + 0.04% BSA (Sigma, A9418) were added to each C-tube 685 and then sample solution was filtered through a 70µm strainer to remove undissociated 686 tissue and debris. Dissociated and strained cell mixtures were then centrifuged for two 687 minutes at 300g and resuspended in 1mL DPBS + 0.04% BSA. Additional cell filtration 688 steps was performed to remove fine cell debris using a 40 µm Flowmi® cell strainer 689 (Sigma, BAH136800040). We found repeating this filtration step twice yielded a cell 690 suspension devoid of cell debris for all lines. The concentration and viability of each 691 suspension was then manually determined using trypan blue staining and a 692 hemocytometer. Finally, samples were diluted to achieve a concentration of 1,000 693 cells/µL. Approximately 10,000 cells were used to generate single cell RNA-seg libraries 694 using the 10x chromium single cell 3' V2 library kit (10X Genomics) according to the 695 manufacturer's instructions and sequencing was performed on a NovaSeg 6000 System 696 (Illumina).

697

#### 698 Single-cell RNA sequencing data processing and analysis.

699 Raw base call sequencing data were demultiplexed with Cellranger (v6.0.0) mkfastg 700 function and aligned by CellRanger (v6.0.0) count function using default settings and 701 the GRCh38-2020-A reference transcriptome from 10x Genomics. Summary by sample: 702 Parental control – 17,066 cells, 23,427 mean reads per cell, 2,370 median genes per 703 cell, 5,850 median UMI counts per cell; Proband – 10,542 cells, 37,722 mean reads per 704 cell, 3,300 median genes per cell, 9,578 median UMI counts per cell; GC control -705 14,124 cells, 27,886 mean reads per cell, 2,780 median genes per cell, 6,556 median 706 UMI counts per cell. The count matrices were then converted to objects in Seurat v3.3.0 <sup>64,65</sup> for analysis and to generate visual representations. Standard quality control 707 708 parameters were applied to each object. In brief, cells with greater than 200 and less 709 than 5,000 unique features or less than 20% mitochondrial reads were retained. The 710 data were log-normalized with a scale factor of 10,000 and the top 2,000 variable 711 features per object were identified. Integration anchors were generated with 30 principal 712 components and used to integrate all samples into a combined object with a total of 713 35,633 cells. Standard Seurat procedures were applied to perform a principal 714 component analysis and KNN unbiased clustering. The FindNeighbors (PCA reduction, 715 30 dimensions) and FindClusters (0.5 resolution, 30 dimensions) functions were used to 716 identify 24 unbiased clusters. Cluster identities were determined by characteristic canonical markers<sup>38,66-68</sup> and 5 unique clusters were identified. Given the scope of the 717 718 study, we opted to utilize a subset object with 17,752 cells that exclusively contained 719 clusters relevant to our focus on progenitor-to-neuron differentiation. This subset object 720 contained immature neurons, intermediate progenitor cells, and three classes of neural 721 progenitor cells.

722

#### 723 Fetal brain and COs transcriptome analyses.

724 Single-cell transcriptomic analyses of fetal brain cortex and COs were carried out on a dataset<sup>19</sup> 725 publicly available (downloaded large, from https://cells.ucsc.edu/organoidreportcard/). The data were handled in Seurat<sup>64</sup> (v3.2.2) 726 727 with R version 4.0.2 with a publicly available dataset. The fetal dataset was comprised 728 of 189,409 cells from various cortical regions of five unique fetal donors between weeks 6-22 of gestation. The organoid dataset was comprised of 235,121 cells from 37 729

organoids across a developmental time window spanning 3-10 weeks of culture. Cellidentities were assigned based on the meta data provided by Bhaduri et al.

- 732
- 733

#### 734 Statistical analyses.

735 GraphPad Prism v9.0.0 (La Jolla, CA) was used to generate all graphs and perform all 736 data and statistical analyses in this study. For organoid growth analyses, the number of 737 replicates displayed in Figure 2 ranged from 19-53 from each group. Statistical analysis 738 of data of organoid growth was performed using a Mann-Whitney U test. Statistically 739 significant differences between parental control and proband COs were observed 740 between groups commencing at day 20, p values are displayed in Fig.2d.  $*p \le 0.05$ ; \*\*p741  $\leq$  0.01; \*\*\*p  $\leq$  0.001; \*\*\*\*p  $\leq$  0.0001; ns=not significant. For organoid growth analyses 742 in Fig.4r, the number of replicates ranged from 44-65 from each group at day 30. 743 Statistical analyses were performed using one-way ANOVA with Tukey's multiple 744 comparisons test (n = 14 rosettes quantified across a minimum of 4 independent 745 organoids per group and 1 independent experiment performed). Statistical analyses for 746 guantification of EdU+ and pHH3+ NPCs in neural rosettes of organoids was performed 747 using one-way ANOVA with Tukey's multiple comparisons test (minimum of n = 4748 independent organoids per group and 3 independent experiments performed). Cilia 749 length quantifications in neural rosettes of organoids were performed using one-way 750 ANOVA with Tukey's multiple comparisons test (minimum of n = 4 independent 751 organoids per group and 1 independent experiment performed). Analysis of single-cell 752 RNA sequencing data are described in detail within the methods section. Eight 753 individual organoids were pooled per group consisting of parental control, proband and 754 GC control organoid groups. In all differential expression data analysis and Metascape 755 gene ontology analyses, p values were adjusted for multiple test correction. Significance 756 of differentially expressed genes was defined as adjusted p < 0.05.

757

#### 758 Acknowledgements

759 We are grateful to all laboratory members for their advice and constructive critiques 760 related to this study. We would especially like to thank Arelis Berrios Hester for her

761 excellent editorial assistance. Figures 2 and 4 contain schematics that were created762 with BioRender.com.

763

#### 764 Author Contributions

765 S.R.F., W.S., D.J., T.B., and M.E.H. conceived and designed the experiments. S.R.F., 766 W.S., M.E.H. D.J., J.W., T.B., K.E.M., P.W., D.C.K., R.N., and J.F performed the 767 research. S.R.F., M.E.H, W.S., D.J., J.W., T.B., K.E.M., P.W., D.C.K., R.N., S.R., 768 M.N.K., S.E.H., and J.F analyzed the data. S.R.F., W.S., D.J., D.C.K., and M.E.H. wrote 769 the manuscript. All authors provided a critical review and approval of the final 770 manuscript for publication. This bench science and clinical research team works in the 771 Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children's 772 Hospital. The institute is generously supported by the Nationwide Foundation Pediatric 773 Innovation Fund.

774

#### 775 Competing interests

The authors report no competing interests.

- 777
- 778

#### 779 **REFERENCES**

- 780
- Sultana, R. *et al.* Identification of a novel gene on chromosome 7q11.2
  interrupted by a translocation breakpoint in a pair of autistic twins. *Genomics* 80, 129-134, doi:10.1006/geno.2002.6810 (2002).
- 7842Gao, Z. et al. An AUTS2-Polycomb complex activates gene expression in the<br/>CNS. Nature **516**, 349-354, doi:10.1038/nature13921 (2014).
- Beunders, G. *et al.* Exonic deletions in AUTS2 cause a syndromic form of
  intellectual disability and suggest a critical role for the C terminus. *Am J Hum Genet* 92, 210-220, doi:10.1016/j.ajhg.2012.12.011 (2013).
- Monderer-Rothkoff, G. *et al.* AUTS2 isoforms control neuronal differentiation. *Mol Psychiatry* 26, 666-681, doi:10.1038/s41380-019-0409-1 (2021).
- Figure 5
  Beunders, G. *et al.* A detailed clinical analysis of 13 patients with AUTS2 syndrome further delineates the phenotypic spectrum and underscores the behavioural phenotype. *J Med Genet* 53, 523-532, doi:10.1136/jmedgenet-2015-103601 (2016).
- 7956Hori, K. et al. Cytoskeletal regulation by AUTS2 in neuronal migration and<br/>neuritogenesis. Cell Rep 9, 2166-2179, doi:10.1016/j.celrep.2014.11.045 (2014).
- 797 7 Schumann, G. *et al.* Genome-wide association and genetic functional studies
  798 identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of
  799 alcohol consumption. *Proc Natl Acad Sci U S A* **108**, 7119-7124,
  800 doi:10.1073/pnas.1017288108 (2011).
- 801 8 Chen, Y. H., Liao, D. L., Lai, C. H. & Chen, C. H. Genetic analysis of AUTS2 as a susceptibility gene of heroin dependence. *Drug Alcohol Depend* 128, 238-242, doi:10.1016/j.drugalcdep.2012.08.029 (2013).
- 804 9 Mefford, H. C. *et al.* Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. *PLoS Genet* 6, e1000962, doi:10.1371/journal.pgen.1000962 (2010).
- 80710Zhang, B. et al. Association study identifying a new susceptibility gene (AUTS2)808for schizophrenia. Int J Mol Sci 15, 19406-19416, doi:10.3390/ijms151119406809(2014).
- Normalia Strategy Str
- 813 12 Talkowski, M. E. *et al.* Sequencing chromosomal abnormalities reveals
  814 neurodevelopmental loci that confer risk across diagnostic boundaries. *Cell* 149,
  815 525-537, doi:10.1016/j.cell.2012.03.028 (2012).
- 816 13 Girirajan, S. et al. Relative burden of large CNVs on а range of 817 neurodevelopmental phenotypes. PLoS Genet 7, e1002334. 818 doi:10.1371/journal.pgen.1002334 (2011).
- 819 14 Castanza, A. S. *et al.* AUTS2 Regulates RNA Metabolism and Dentate Gyrus 820 Development in Mice. *Cereb Cortex*, doi:10.1093/cercor/bhab124 (2021).

- 821 15 Oksenberg, N., Stevison, L., Wall, J. D. & Ahituv, N. Function and regulation of
  822 AUTS2, a gene implicated in autism and human evolution. *PLoS Genet* 9,
  823 e1003221, doi:10.1371/journal.pgen.1003221 (2013).
- Hori, K. *et al.* AUTS2 Regulation of Synapses for Proper Synaptic Inputs and
  Social Communication. *iScience* 23, 101183, doi:10.1016/j.isci.2020.101183
  (2020).
- Pollen, A. A. *et al.* Establishing Cerebral Organoids as Models of Human-Specific
  Brain Evolution. *Cell* **176**, 743-756.e717, doi:10.1016/j.cell.2019.01.017 (2019).
- 829 18 Camp, J. G. *et al.* Human cerebral organoids recapitulate gene expression
  830 programs of fetal neocortex development. *Proc Natl Acad Sci U S A* **112**, 15672831 15677, doi:10.1073/pnas.1520760112 (2015).
- 832 19 Bhaduri, A. *et al.* Cell stress in cortical organoids impairs molecular subtype 833 specification. *Nature* **578**, 142-148, doi:10.1038/s41586-020-1962-0 (2020).
- Eze, U. C., Bhaduri, A., Haeussler, M., Nowakowski, T. J. & Kriegstein, A. R.
  Single-cell atlas of early human brain development highlights heterogeneity of
  human neuroepithelial cells and early radial glia. *Nat Neurosci* 24, 584-594,
  doi:10.1038/s41593-020-00794-1 (2021).
- 83821Lancaster, M. A. *et al.* Cerebral organoids model human brain development and<br/>microcephaly. *Nature* **501**, 373-379, doi:10.1038/nature12517 (2013).
- Zhang, W. *et al.* Modeling microcephaly with cerebral organoids reveals a
  WDR62-CEP170-KIF2A pathway promoting cilium disassembly in neural
  progenitors. *Nat Commun* **10**, 2612, doi:10.1038/s41467-019-10497-2 (2019).
- Wang, L. *et al.* Loss of NARS1 impairs progenitor proliferation in cortical brain
  organoids and leads to microcephaly. *Nat Commun* **11**, 4038,
  doi:10.1038/s41467-020-17454-4 (2020).
- 846 24 Gabriel, E., Ramani, A., Altinisik, N. & Gopalakrishnan, J. Human Brain
  847 Organoids to Decode Mechanisms of Microcephaly. *Front Cell Neurosci* 14, 115,
  848 doi:10.3389/fncel.2020.00115 (2020).
- B49 25 Doobin, D. J., Kemal, S., Dantas, T. J. & Vallee, R. B. Severe NDE1-mediated
  microcephaly results from neural progenitor cell cycle arrests at multiple specific
  stages. *Nat Commun* 7, 12551, doi:10.1038/ncomms12551 (2016).
- 852 26 Merfeld, E., Ben-Avi, L., Kennon, M. & Cerveny, K. L. Potential mechanisms of
  853 Zika-linked microcephaly. Wiley Interdiscip Rev Dev Biol 6,
  854 doi:10.1002/wdev.273 (2017).
- 855 27 Kopanos, C. *et al.* VarSome: the human genomic variant search engine. 856 *Bioinformatics* **35**, 1978-1980, doi:10.1093/bioinformatics/bty897 (2019).
- 857 28 Fair, S. R. *et al.* Electrophysiological Maturation of Cerebral Organoids
  858 Correlates with Dynamic Morphological and Cellular Development. *Stem Cell*859 *Reports* 15, 855-868, doi:10.1016/j.stemcr.2020.08.017 (2020).
- Qian, X. *et al.* Brain-Region-Specific Organoids Using Mini-bioreactors for
  Modeling ZIKV Exposure. *Cell* 165, 1238-1254, doi:10.1016/j.cell.2016.04.032
  (2016).
- 30 Hill, R. S. & Walsh, C. A. Molecular insights into human brain evolution. *Nature* 437, 64-67, doi:10.1038/nature04103 (2005).

- Kriegstein, A., Noctor, S. & Martinez-Cerdeno, V. Patterns of neural stem and
  progenitor cell division may underlie evolutionary cortical expansion. *Nat Rev Neurosci* 7, 883-890, doi:10.1038/nrn2008 (2006).
- Penisson, M., Ladewig, J., Belvindrah, R. & Francis, F. Genes and Mechanisms
  Involved in the Generation and Amplification of Basal Radial Glial Cells. *Front Cell Neurosci* 13, 381, doi:10.3389/fncel.2019.00381 (2019).
- 33 Gabriel, E. *et al.* Recent Zika Virus Isolates Induce Premature Differentiation of
  Neural Progenitors in Human Brain Organoids. *Cell stem cell* 20, 397-406 e395,
  doi:10.1016/j.stem.2016.12.005 (2017).
- 87434Gabriel, E. et al. CPAP promotes timely cilium disassembly to maintain neural875progenitor pool. EMBO J 35, 803-819, doi:10.15252/embj.201593679 (2016).
- 35 Jayaraman, D. *et al.* Microcephaly Proteins Wdr62 and Aspm Define a Mother
  877 Centriole Complex Regulating Centriole Biogenesis, Apical Complex, and Cell
  878 Fate. *Neuron* 92, 813-828, doi:10.1016/j.neuron.2016.09.056 (2016).
- Shohayeb, B. *et al.* The association of microcephaly protein WDR62 with
  CPAP/IFT88 is required for cilia formation and neocortical development. *Hum Mol Genet* 29, 248-263, doi:10.1093/hmg/ddz281 (2020).
- 88237Sivitilli, A. A. *et al.* Robust production of uniform human cerebral organoids from883pluripotent stem cells. *Life Sci Alliance* **3**, doi:10.26508/lsa.202000707 (2020).
- 88438Velasco, S. et al. Individual brain organoids reproducibly form cell diversity of the885human cerebral cortex. Nature, doi:10.1038/s41586-019-1289-x (2019).
- Arai, Y. *et al.* Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. *J Neurosci* 25, 9752-9761, doi:10.1523/JNEUROSCI.2512-05.2005 (2005).
- 88940Jo, A. et al. The versatile functions of Sox9 in development, stem cells, and890human diseases. Genes Dis 1, 149-161, doi:10.1016/j.gendis.2014.09.004891(2014).
- Kaplan, E. S., Ramos-Laguna, K. A., Mihalas, A. B., Daza, R. A. M. & Hevner, R.
  F. Neocortical Sox9+ radial glia generate glutamatergic neurons for all layers, but
  lack discernible evidence of early laminar fate restriction. *Neural Dev* 12, 14,
  doi:10.1186/s13064-017-0091-4 (2017).
- Wiszniak, S. & Schwarz, Q. Notch signalling defines dorsal root ganglia
  neuroglial fate choice during early neural crest cell migration. *BMC Neurosci* 20, 21, doi:10.1186/s12868-019-0501-0 (2019).
- Kishi, Y., Fujii, Y., Hirabayashi, Y. & Gotoh, Y. HMGA regulates the global chromatin state and neurogenic potential in neocortical precursor cells. *Nat Neurosci* 15, 1127-1133, doi:10.1038/nn.3165 (2012).
- 902 44 Ohtsuka, T. & Kageyama, R. Regulation of temporal properties of neural stem 903 cells and transition timing of neurogenesis and gliogenesis during mammalian 904 Cell neocortical development. Semin Dev Biol 95. 4-11. 905 doi:10.1016/j.semcdb.2019.01.007 (2019).
- 90645Oksenberg, N. et al. Genome-wide distribution of Auts2 binding localizes with907active neurodevelopmental genes. Transl Psychiatry 4, e431,908doi:10.1038/tp.2014.78 (2014).
- 909 46 Chenn, A. Wnt/beta-catenin signaling in cerebral cortical development. 910 *Organogenesis* **4**, 76-80, doi:10.4161/org.4.2.5852 (2008).

- Machon, O., van den Bout, C. J., Backman, M., Kemler, R. & Krauss, S. Role of
  beta-catenin in the developing cortical and hippocampal neuroepithelium. *Neuroscience* 122, 129-143, doi:10.1016/s0306-4522(03)00519-0 (2003).
- Woodhead, G. J., Mutch, C. A., Olson, E. C. & Chenn, A. Cell-autonomous betacatenin signaling regulates cortical precursor proliferation. *J Neurosci* 26, 12620-12630, doi:10.1523/JNEUROSCI.3180-06.2006 (2006).
- 917 49 Shtutman, M. *et al.* The cyclin D1 gene is a target of the beta-catenin/LEF-1 918 pathway. *Proc Natl Acad Sci U S A* **96**, 5522-5527, doi:10.1073/pnas.96.10.5522 919 (1999).
- 92050Tetsu, O. & McCormick, F. Beta-catenin regulates expression of cyclin D1 in<br/>colon carcinoma cells. *Nature* **398**, 422-426, doi:10.1038/18884 (1999).
- 922 51 Bohrer, C. *et al.* The balance of Id3 and E47 determines neural stem/precursor
  923 cell differentiation into astrocytes. *EMBO J* 34, 2804-2819,
  924 doi:10.15252/embj.201591118 (2015).
- 925 52 Wu, Y., Liu, Y., Levine, E. M. & Rao, M. S. Hes1 but not Hes5 regulates an astrocyte versus oligodendrocyte fate choice in glial restricted precursors. *Dev Dyn* 226, 675-689, doi:10.1002/dvdy.10278 (2003).
- 92853Autism Genome Project, C. *et al.* Mapping autism risk loci using genetic linkage929and chromosomal rearrangements. Nat Genet **39**, 319-328, doi:10.1038/ng1985930(2007).
- 931 54 Dean, C. *et al.* Neurexin mediates the assembly of presynaptic terminals. *Nat Neurosci* 6, 708-716, doi:10.1038/nn1074 (2003).
- 93355Deardorff, M. A. et al. Mutations in cohesin complex members SMC3 and934934SMC1A cause a mild variant of cornelia de Lange syndrome with predominant935mental retardation. Am J Hum Genet 80, 485-494, doi:10.1086/511888 (2007).
- 93656Skaar, D. A. et al. Analysis of the RELN gene as a genetic risk factor for autism.937Mol Psychiatry 10, 563-571, doi:10.1038/sj.mp.4001614 (2005).
- 93857Wu, Y. et al. Multi-trait analysis for genome-wide association study of five939psychiatric disorders. Transl Psychiatry 10, 209, doi:10.1038/s41398-020-00902-9406 (2020).
- Hasenpusch-Theil, K. *et al.* Transcriptional analysis of Gli3 mutants identifies
  Wnt target genes in the developing hippocampus. *Cereb Cortex* 22, 2878-2893, doi:10.1093/cercor/bhr365 (2012).
- 94459Dubruc, E. et al. A new intellectual disability syndrome caused by CTNNB1945haploinsufficiency. Am J Med Genet A 164A, 1571-1575,946doi:10.1002/ajmg.a.36484 (2014).
- 94760Kuechler, A. *et al.* De novo mutations in beta-catenin (CTNNB1) appear to be a948frequent cause of intellectual disability: expanding the mutational and clinical949spectrum. Hum Genet **134**, 97-109, doi:10.1007/s00439-014-1498-1 (2015).
- Sanxiong Liu, K. A. A., Chi Vicky Cheng, Takae Kiyama, Mitali Dave, Hanna K.
  McNamara, Stefano G Caraffi, Ivan Ivanovski, Edoardo Errichiello, Christiane
  Zweier, Orsetta Zuffardi, Michael Schneider, Antigone S. Papavasiliou, M. Scott
  Perry, Megan T Cho, Astrid Weber, Andrew Swale, Tudor C. Badea, Chai-An
  Mao, Livia Garavelli, William B Dobyns, Danny Reinberg. NRF1 Association with
  AUTS2-Polycomb Mediates Specific Gene Activation in the Brain. *BioRxiv*https://www.biorxiv.org/content/10.1101/2021.03.30.437620v1.full (2021).

- 957 62 Cingolani, P. et al. A program for annotating and predicting the effects of single 958 nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila 959 w1118; iso-2; melanogaster strain iso-3. Fly (Austin) 6. 80-92. 960 doi:10.4161/fly.19695 (2012).
- 83 Koboldt, D. C. *et al.* A de novo nonsense mutation in ASXL3 shared by siblings
  84 with Bainbridge-Ropers syndrome. *Cold Spring Harb Mol Case Stud* 4, doi:10.1101/mcs.a002410 (2018).
- 96464Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-9651902.e1821, doi:10.1016/j.cell.2019.05.031 (2019).
- Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating singlecell transcriptomic data across different conditions, technologies, and species. *Nature Biotechnology* 36, 411-420, doi:10.1038/nbt.4096 (2018).
- 969 66 Quadrato, G. *et al.* Cell diversity and network dynamics in photosensitive human 970 brain organoids. *Nature* **545**, 48-53, doi:10.1038/nature22047 (2017).
- 971 67 Xiang, Y. *et al.* Fusion of Regionally Specified hPSC-Derived Organoids Models
  972 Human Brain Development and Interneuron Migration. *Cell stem cell* 21, 383-398
  973 e387, doi:10.1016/j.stem.2017.07.007 (2017).
- 974
   68
   Cakir, B. *et al.* Engineering of human brain organoids with a functional vascular 

   975
   like system. Nat Methods 16, 1169-1175, doi:10.1038/s41592-019-0586-5

   976
   (2019).
- 977 978

#### 979 **Figure legends** 980

981 Figure 1. Identification of a de novo AUTS2 variant within a conserved histidine 982 rich domain. (A) Family pedigree. Circle: female; square: male; filled: affected. (B-C) 983 MRI of affected individual showing reduced cortical area, ventriculomegaly (asterisk) 984 and cerebellar atrophy (arrow). MRI images are arranged in sagittal and coronal planes, 985 respectively. Scale bar = 2 cm. (D) Sanger-based DNA sequence chromatogram of the 986 c.1600A>C AUTS2 variant in exon 9 in the affected patient and absent in her 987 unaffected, healthy parents. (E) AUTS2 genomic organization showing disease-causing 988 variants, key domains, and exon structure of the AUTS2 gene. Pathogenic and likely 989 pathogenic variants from the ClinVar database as of January 2021 are represented by 990 circles and shaded according to variant classes. Proline-rich domains (PR1/PR2) and 991 histidine-rich domains (H1/H2) were obtained from UniProt (entry Q8WXX7). The 992 curated AUTS2 protein family domain from PFAM is shown in yellow. Exon locations 993 and numbering in the bottom panel reflect the canonical full-length transcript 994 (NM 015570.4). (F) AUTS2 amino acid conservation within the H1 domain and

spanning position 534 across multiple species. Arrow represents the AUTS2 T534Palteration in the affected patient.

997

998 Figure 2. AUTS2 patient COs show reduced growth and proliferative deficits. (A) 999 Overview of protocol used to generate COs. Briefly, peripheral blood mononuclear cells 1000 (PBMCs) were isolated from patient and control blood samples and underwent Sendai 1001 virus transduction with Yamanaka factors (OCT3/4, SOX2, KLF4, c-MYC) to produce 1002 induced pluripotent stem cells (iPSCs). These cultures were characterized and then 1003 used to generate COs through undirected, spontaneous differentiation. (B-C) 1004 Representative images of parental control COs and proband COs at Day 34 showing a 1005 significant growth reduction in proband COs. Scale bar = 1 mm. (**D**) Growth trajectory 1006 analysis of parental control and proband COs from days 16-37 in CO development. (E-1007 F) Parental control COs show proliferating neural progenitors identified as EdU+ and 1008 phospho-Histone H3+ (pHH3; mitosis marker) compared to proband COs, which show a 1009 reduction (quantified in **G** and **H**). Scale bar = 50  $\mu$ m. DAPI (blue) stains nuclei. All data 1010 are shown as the mean ± standard deviation (SD). Statistical analyses in panel d were 1011 performed using Mann-Whitney U tests and those in panels g and h were performed 1012 using one-way ANOVA with Tukey's multiple comparisons test (n = 4 independent 1013 organoids per group and 2 independent experiments performed). Statistically significant 1014 differences between parental control and proband COs were observed between groups 1015 commencing at day 20.  $*p \le 0.05$ ;  $**p \le 0.01$ ;  $***p \le 0.001$ ;  $****p \le 0.0001$ .

1016

1017 Figure 3. AUTS2 patient COs show functional and molecular deficits in neural 1018 progenitor cells. (A) The fate of neural progenitor daughter cells correlates with their 1019 mitotic division class. Symmetric divisions (top) give rise to two daughter apical 1020 progenitors whereas asymmetric divisions (bottom) give rise to a single apical 1021 progenitor and one mature cell type (intermediate progenitor or neuron). (B-C) 1022 Representative mitotic divisions at the apical surface of parental control and proband 1023 rosettes of COs. The division class is determined by the acute angle,  $\theta_a$ , that forms 1024 between the cleavage plane (defined by TPX2+ mitotic poles, green) and the apical 1025 surface (marked by ZO1, red). Cell nuclei visualized with DAPI (blue). Scale bar = 50

1026 um and 10 µm for lower and higher magnification images, respectively. (**D**) Asymmetric 1027 obligue and vertical divisions are overrepresented in proband COs (65%) compared to 1028 parental control COs (36%). (E-F) Acetylated tubulin (AcTub) staining reveals normal 1029 rosette microtubular organization within parental control COs, but severely disrupted 1030 organization in proband COs (G-H). Scale bar =  $250 \mu m$ . (I) SOX2+ neural progenitors 1031 (red) within rosettes of parental control COs form robust, uniform ARLB13B+ cilia 1032 (green) at the apical surface, whereas those within rosettes of proband COs show 1033 shortened and irregular arrangement (**J**). Scale bar = 10  $\mu$ m. (**K**) Proband cilia show a 1034 statistically significant reduction in length compared to parental control cilia. All data are 1035 shown as the mean ± SD. Statistical analysis of cilia quantification data was performed 1036 using an unpaired t-test (n =540 parental control cilia and n=191 proband cilia quantified 1037 across 4 independent organoids per group and 1 independent experiment performed). 1038 \*\*\*\*p ≤ 0.0001.

1039

1040 Figure 4. AUTS2 gene editing with CRISPR-Cas9 rescues proband COs 1041 phenotypes. (A) CRISPR-Cas9-mediated homology directed repair gene correction 1042 strategy (B) Chromatogram generated by Sanger sequencing of affected patient 1043 (AUTS2 c.1600A>C, proband) and GC hiPSC line. First arrow denotes the C>A base 1044 pair change at c.1600 and the second arrow denotes the silent gene edit (G>A) at 1045 c.1608. (C-G) Schematic showing major steps in an optimized protocol to generate 1046 reproducible COs from hiPSCs with representative culture phase contrast microscopic 1047 images below each step. Scale bar = 200  $\mu$ m and 500  $\mu$ m for (D) and (E-G), 1048 respectively. (H,I,J) Representative images of parental control, proband, and GC control 1049 COs at Day 30, cross-sectional area of each CO group quantified in (Q). (K,L,M) 1050 Decreased percentage of EdU+ and phospho-Histone H3+ (pHH3; red, mitosis marker) 1051 progenitors in proband CO rosettes compared to parental and GC controls. Scale bar = 1052 200  $\mu$ m. Magnified in (N), (O) and (P), scale bar = 50  $\mu$ m; quantified in (R) and (S). All 1053 data are shown as the mean  $\pm$  SD. Statistical analyses were performed using one-way ANOVA with Tukey's multiple comparisons test (n = 14 rosettes quantified across a 1054 1055 minimum of 4 independent organoids per group and 1 independent experiment performed).  $***p \le 0.001$ ;  $****p \le 0.0001$ ; ns=not significant. 1056

#### 1057

1058 Figure 5. Single-cell RNA sequencing reveals an underrepresented population of 1059 proliferative neural progenitor cells in proband COs. (A) UMAP plot of key cell types 1060 organized into five major clusters: Intermediate progenitors, immature neurons, and 1061 three classes of neural progenitor cells containing 17,752 cells. (B) Select canonical 1062 markers used to determine cluster identities. MKI67 and TOP2A show enriched 1063 expression within Type 1 neural progenitor cells, CDK6 shows enriched expression in 1064 Type 2 neural progenitor cells and SOX9 shows enriched expression in Type 3 neural 1065 progenitor cells; SOX2 is a pan-progenitor marker; EOMES (TBR2) labels Intermediate 1066 Progenitors; STMN2 and TBR1 label Immature Neurons. (C-E) UMAP plots of cells from 1067 parental control COs (8,523 cells), proband COs (3,754 cells) and GC control COs 1068 (5,475 cells). Type 2 neural progenitors are outlined in each plot to highlight their 1069 underrepresentation in proband COs. (F-H) Percentages of cell types per group. (I) GO 1070 terms identified in Type 2 neural progenitors enriched for genes associated with G1/S 1071 cell cycle phase transition. (source: Metascape) (J) Differentially expressed genes and 1072 associated information identified in the G1/S transition of the mitotic cell cycle gene 1073 ontology. (K) Feature plots showing expression of G1/S cell cycle genes in proband and 1074 GC control COs.

1075

1076 Figure 6. Deficits in WNT- $\beta$  Catenin pathway gene expression in AUTS2 patient 1077 COs. (A) GO terms identified in Type 1 neural progenitors enriched for genes 1078 associated with the WNT- $\beta$  Catenin signaling among others. (B) Violin plots of DEGs in 1079 progenitors shows chromatin modifying genes: HIST1H2AG, Type 1 neural 1080 KCNQ10T1, and HMGA1; transcriptional regulator, TSHZ2, which has been identified 1081 as an AUTS2 target gene; and genes associated with neural and glial differentiation: 1082 FGFR3, NFIB, MAP2; and cell adhesion: CNTNAP2, also identified as an AUTS2 target 1083 gene. (C) Heat maps of Type 1 neural progenitor DEGs in proband and control COs 1084 show alterations in gene expression associated with WNT-β Catenin signaling. Feature 1085 and violin plots of CTNNB1 gene expression in Type 1 and 3 neural progenitors, and 1086 immature neurons shows reduced expression in proband COs compared to controls. 1087 (D) Schematic showing the WNT- $\beta$  Catenin pathway and color-coded Type 1 neural

1088 progenitor DEGs (Red=up-regulated and green=down-regulated). (E) GO terms 1089 identified in Type 3 neural progenitors enriched for genes associated with the canonical 1090 WNT signaling pathway, regulation of glial cell differentiation, and others. (F) Violin plots 1091 of DEGs in Type 3 neural progenitors show NOTCH signaling transcription factor, 1092 HES1, and ID3, which regulate glial differentiation; genes regulating cellular division: 1093 CENPF and CENPW: chromatin modifying gene, HMGA1: and WNT signaling 1094 regulators: RSPO3, SFRP2, and ZIC1 (G) GO terms identified in immature neurons 1095 enriched for genes associated with synapse maturation, cholesterol metabolism, 1096 cytoskeletal organization, and others. (H) Violin plots of DEGs in immature neurons 1097 shows genes associated with synapse maturation: NEFM, RELN, and NRXN1; 1098 cholesterol biosynthesis: ACAT2 and HMGCS1; and genes associated with cytoskeletal 1099 organization: SMC1A and NEFM; and neurite morphogenesis: DCC and MDK. Of note, 1100 NRXN1 (AUTS2 target gene), DCC, RELN (AUTS2 target gene), and SMC1A are also 1101 designated SFARI genes implicated in autism spectrum disorder and intellectual 1102 disability. Log<sub>2</sub> fold changes (FC) are shown under each violin plot and denote FC 1103 relative to either the parental control or gene corrected control.

1104

1105













-0.36 -0.33

-0.43 -0.35

-0.84 -0.35

-0.44 -0.38